|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����� |
|
����������� |
| ��������������� | |
|
������ |
|
���� |
| PubMed | |
|
Article by SHE Xiao-dong |
|
Article by LIU Wei-da |
����ģ����������о�
������, ����
1. ����Ƥ����ҽԺ 116021;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
���Ｒ��ģ����Ҫ����ʵ������ѧ��ʵ�鲡��ѧ��ʵ������ѧ����ҩɸѡ���о�,����ʵ���������༲�����бȽ��о�,�����ڸ�����,����Ч����ʶ���༲���ķ�����չ����,�о����δ�ʩ���������Ϊ�����²�,�����Ž����������շ����ص�����,ʹ�����ȫ��ɢ�������Ⱦ�������ࡣ�����������ķ�������������������,����ģ��Ӧ����������о�,��Ϊ����һ����������������²�����,Ϊ�ٴ��ṩ���õ������ֶδ��»�����
Animal Models and Mycosis Research
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
The animal model is an animal that can simulate human disease. It is mainly used in the study on experimental physiology, experimental pathology, experimental therapeutics and new drug screening. Comparing the results of the experiments with human diseases will help to understand the occurrence and development of human diseases, as well as to investigate the prevention and treatment of these diseases more conveniently and efficiently. Mycoses usually happen under certain conditions. However, with the recent increase of various inducing factors, deep and disseminated fungal infections have also increased day by day. The pathogenesis of many fungal diseases is unclear until now. Applying animal models into fungal disease research may provide favourable ground for the interpretation of the pathogenesis and offer preferable therapeutic tools for clinic practice.
[2] Svecova D.Experimental Trichophyton rubrum infection in animals.Epidemiol Mikrobiol Imunol,2000,49:75-79.
[3] Majima T,Masui S,Uchida K,et al.A novel mycological analysis valuable for evaluating therapeutic efficacy of antimycotics against experimental dermatophytosis in guinea pigs.Mycoses,2005,48:108-113.
[4] Tatsumi Y,Yokoo M,Arika T,et al.In vitro antifungal activity of KP-103,a novel triazole derivative,and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.Antimicrob Agents Chemother,2001,45:1493-1499.
[5] Tatsumi Y,Yokoo M,Arika T,et al.In vivo fungicidal effect of KP-103 in a guinea pig model of interdigital tinea pedis determined by using a new method for removing the antimycotic carryover effect.Microbiol Immunol,2002,46:433-439.
[6] Uchida K,Tanaka T,Yamaguchi H.Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model oftinea pedis.Microbiol Immunol,2003,47:143-146.
[7] Fidel PL Jr,Barousse M,Espinosa T,et al.An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis ofvulvovaginal candidiasis.Infect Immun,2004,72:2939-2946.
[8] De Bernardis F,Boccanera M,Adriani D,et al.Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis.Infect Immun,2002,70:2725-2729.
[9] Fidel PL Jr,Cutright JL,Tait L,et al.A murine model of Candida glabrata vaginitis.J Infect Dis,1996,173:425-431.
[10] Brun S,Dalle F,Saulnier P,et al.Biological consequences of petite mutations in Candida glabrata.J Antimicrob Chemother,2005,56:307-314.
[11] Spellberg B,Ibrahim AS,Edwards JE Jr,et al.Mice with disseminated candidiasis die of progressive sepsis.J Infect Dis,2005,192:336.
[12] Netea MG,Sutmuller R,Hermann C,et al.Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells.J Immunol,2004,172:3712-3718.
[13] Green CB,Zhao X,Hoyer LL.Use of green fluorescent protein and reverse transcription-PCR to monitor Candida albicans agglutinin-like sequence gene expression in a murine model of disseminated candidiasis.Infect Immun,2005,73:1852-1855.
[14] Huppert M,Sun SH,Gross AJ.Evaluation of an experimental animal model for testing antifungal substances.Antimicrob Agents Chemother,1972,1:367-372.
[15] Fierer J,Walls L,Wright F,et al.Genes influencing resistance to Coccidioides immitis and the interleukin-10 response map to chromosomes 4 and 6 in mice.Infect Immun,1999,67:2916-2919.
[16] Clemons KV,Stevens DA.Efficacies of sordarin derivatives GM193663,GM211676,and GM237354 in a murine model of systemic coccidioidomycosis.p6.Antimicrob Agents Chemother,2000,44:1874-1877.
[17] Clemons KV,Stevens DA.Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.Antimicrob Agents Chemother,1991,35:1829-1833.
[18] Sorensen KN,Sobel RA,Clemons KV,et al.Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model.Antimicrob Agents Chemother,2000,44:3087-3091.
[19] Deepe GS Jr,Gibbons RS.et al.Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasma capsulatum.Infect Immun,2002,70:3759-3767.
[20] Medeiros AI,Sa-Nunes A,Soares EG,et al.Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis.Infect Immun,2004,72:1637-1644.
[21] Durkin MM,Connolly PA,Karimi K,et al.Pathogenic differences between North American and Latin American strains of Histoplasma capsulatum var.capsulatum in experimentally infected mice.J Clin Microbiol,2004,42:4370-4373.
[22] Waldorf AR,Ruderman N,Diamond RD.Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.J Clin Invest,1984,74:150-160.
[23] Feldmesser M,Kress Y,NovikoffP,et al.Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection.Infect Immun,2000,68:4225-4237.
[24] Dixon DM,Duncan RA,Hurd NJ.Use of a mouse model to evaluate clinical and environmental isolates of Sporothrix spp.from the largest U.S.epidemic of sporotrichosis.J Clin Microbiol,1992,30:951-954.
[25] Carrillo-Munoz AJ,Giusiano G,Ezkurra PA,et al.Sertaconazole:updated review of a topical antifungal agent.Expert Rev Anti Infect Ther,2005,3:333-342.
[26] Cardona-Castro N,Agudelo-Florez P.Development of a chronic chromoblastomycosis model in immunocompetent mice.Med Mycol,1999,37:81-83.